SCHEMBL4067920 — predicted protein targets

Predicted protein targets (top 18)

	gene	UniProt	supporting neighbours	confidence
▸	L3MBTL1	Q9Y468	3/20	0.44

▸	RAPGEF4	Q8WZA2	1/20	0.40

▸	KMT2A	Q03164	3/20	0.38

▸	LMNA	P02545	2/20	0.38

▸	KDM4E	B2RXH2	1/20	0.38

▸	TSHR	P16473	1/20	0.38

▸	ALDH1A1	P00352	4/20	0.37

▸	PIK3C3	Q8NEB9	1/20	0.36

▸	NOD1	Q9Y239	2/20	0.36

▸	POLB	P06746	1/20	0.36

▸	ALDH3A1	P30838	1/20	0.36

▸	HTT	P42858	1/20	0.36

▸	MEN1	O00255	1/20	0.36

▸	HTR6	P50406	1/20	0.35

▸	NOD2	Q9HC29	1/20	0.35

▸	CD4	P01730	2/20	0.35

▸	BRD4	O60885	1/20	0.35

▸	PKM	P14618	1/20	0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL13769391	0.89	L3MBTL1 (0.46)	L3MBTL1RAPGEF4KMT2ALMNAKDM4E
SCHEMBL15428434	0.86	L3MBTL1 (0.48)	L3MBTL1RAPGEF4KDM4ETSHRNOD1
SCHEMBL3556162	0.82	L3MBTL1 (0.49)	L3MBTL1RAPGEF4TSHRNOD1POLB
SCHEMBL4068111	0.82	L3MBTL1 (0.49)	L3MBTL1RAPGEF4KDM4ETSHRALDH1A1
SCHEMBL4119927	0.81	L3MBTL1 (0.45)	L3MBTL1RAPGEF4KMT2ATSHRNOD1
SCHEMBL13960904	0.81	L3MBTL1 (0.45)	L3MBTL1RAPGEF4KMT2ATSHRALDH1A1
SCHEMBL24262373	0.80	L3MBTL1 (0.43)	L3MBTL1RAPGEF4KMT2ALMNAKDM4E
SCHEMBL30575111	0.80	L3MBTL1 (0.43)	L3MBTL1RAPGEF4KMT2ALMNAKDM4E
SCHEMBL24262374	0.80	L3MBTL1 (0.43)	L3MBTL1RAPGEF4KMT2ALMNAKDM4E
SCHEMBL13494114	0.78	L3MBTL1 (0.50)	L3MBTL1RAPGEF4TSHRALDH1A1NOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20140315931-A1	DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-10-23	—	—	US	disclosed
US-20140315931-A1	DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-10-23	—	—	US	disclosed
US-20140315931-A1	DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-10-23	—	—	US	disclosed
US-20140171454-A1	Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-06-19	—	—	US	disclosed
US-20140171454-A1	Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-06-19	—	—	US	disclosed
US-20140171454-A1	Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-06-19	—	—	US	disclosed
US-8741912-B2	Deazapurines useful as inhibitors of Janus kinases	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-06-03	—	—	US	disclosed
US-8741912-B2	Deazapurines useful as inhibitors of Janus kinases	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-06-03	—	—	US	disclosed
US-8741912-B2	Deazapurines useful as inhibitors of Janus kinases	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-06-03	—	—	US	disclosed
US-8633205-B2	Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-01-21	—	—	US	disclosed
EP-1844050-B1	PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE	VERTEX PHARMA (US)	2009-01-14	—	—	EP	disclosed
EP-2001884-A1	DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES	Vertex Pharmaceuticals, Inc. (US)	2008-12-17	—	—	EP	disclosed
WO-2007117494-A1	DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES	VERTEX PHARMACEUTICALS INCORPORATED (US)	2007-10-18	—	—	WO	disclosed
WO-2007117494-A1	DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES	VERTEX PHARMACEUTICALS INCORPORATED (US)	2007-10-18	—	—	WO	disclosed
EP-1844050-A1	PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE	Vertex Pharmaceuticals, Inc. (US)	2007-10-17	—	—	EP	disclosed
US-20070004762-A9	Pyrrolopyrimidines useful as inhibitors of protein kinase	VERTEX PHARMACEUTICALS INCORPORATED	2007-01-04	—	—	US	disclosed
US-20070004762-A9	Pyrrolopyrimidines useful as inhibitors of protein kinase	VERTEX PHARMACEUTICALS INCORPORATED	2007-01-04	—	—	US	disclosed
US-20070004762-A9	Pyrrolopyrimidines useful as inhibitors of protein kinase	VERTEX PHARMACEUTICALS INCORPORATED	2007-01-04	—	—	US	disclosed
WO-2006096270-A1	PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE	VERTEX PHARMACEUTICALS INCORPORATED (US)	2006-09-14	—	—	WO	disclosed
US-20060183761-A1	Pyrrolopyrimidines useful as inhibitors of protein kinase	LEDEBOER MARK	2006-08-17	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20070004762-A9	Pyrrolopyrimidines useful as inhibitors of protein kinase	PRKDC, MAP3K20, MAP3K5	L3MBTL1 2911/4885RAPGEF4 1036/4885KMT2A 1671/4885
US-20140315931-A1	DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES	JAK1, JAK3, JAK2	L3MBTL1 2062/4885RAPGEF4 2178/4885KMT2A 608/4885
US-20140171454-A1	Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases	PRKDC, DCK, CDK2	L3MBTL1 2823/4885RAPGEF4 1522/4885KMT2A 1647/4885
US-20060183761-A1	Pyrrolopyrimidines useful as inhibitors of protein kinase	PRKDC, MAP3K20, MAP3K5	L3MBTL1 2911/4885RAPGEF4 1036/4885KMT2A 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.